Enzolytics Inc (ENZC)

[TheCoach]

MAGA, Timing101, and all. Good morning. We have a couple visiting from Boston and one of them is an infectious disease researcher at M.I.T. I was explaining about how ENZC is working on developing an AI platform to identify and isolate immutable target sites of viruses.
Her initial comment was that she prefers "human research over AI" because the research and the platform for identifying and then delivering the intended treatment are all in real time. The binding of proteins and the study of toxicity becomes much more relevant with a human subject, which is why human trials are always the final step in approval.
She began speaking of how big pharma, the algorithms and finally the actuarial approach determine in many cases how drugs are brought to market. There is always a metric concerning toxicity that will determine the efficacy of a drug. I then explained that the active ingredient in the ENZC product line is human, not artificial. That brought a "huh". I showed her some of the research that has been published. From the final toxicity study on IPF Immune:

https://enzoimmune.com/wp-content/uploads/2021/10/finalen-otchet-tzitotoksichen-efekt-na-ipf-eng.pdf

I. Relevance of the problem
One of the biggest challenges facing modern biomedical science is the need to create new, highly effective and well-tolerated drugs for the treatment of viral infections. Despite the significant advantages of chemotherapy, it cannot be considered that any definitive results have been achieved at this stage in
terms of the treatment of viral diseases. Low selectivity, significant toxicity, emergence of resistant mutants, a high number of deaths and the emergence of new zooanthroponotic viruses are among the main reasons for the search for new antiviral agents. In recent years, there has been an increase in research into
the antiviral and immunomodulatory properties of biologically active molecules.

And the conclusion:

IV. Conclusion
The tested Inactivated Pepsin Fragment (IPF) – an active ingredient of the EnzoImmune Active preparation – has shown no toxicity to the Vero cell line at various exposure intervals (24 – 96 hours), as administered in concentrations ranging from 0.0001 mg/mL to 5 mg/mL.

She was very intrigued when I showed her the final reports concerning IPF Immune vs. Remdesivir and Covid:

https://enzoimmune.com/wp-content/uploads/2021/09/final-report-corornavirus.pdf

And the final reports concerning IPF Immune vs. Acyclovir and Herpes:

https://enzoimmune.com/wp-content/uploads/2021/09/final-report-herpes-simplex.pdf

The information is there on the science if you want to take the time. She was impressed with the tests being done on a monolayer cell line of the African Green Monkey as well as the platforms used to perform the tests and bring about the results. All are internationally recognized as being the gold standard of testing platforms. We spoke about HIV and monoclonal antibodies and she was very intrigued that ENZC is developing fully human monoclonal antibodies.
She explained that the main difference in using fully human verses drug treatment is the body"s ability to direct the antibodies to the source of the infection due the treatment curing the body of the disease or infection as opposed to using a drug to try to kill the cells that are infectious. Anyone who has been through, or seen a loved one go through, chemotherapy knows that many patients die from the treatment due to it's toxicity. The next phase in cancer treatment in the immune treatment arena.

Types of cancer immunotherapy
There are several main types of immunotherapy used to treat cancer, and many are being studied.

Checkpoint inhibitors: These drugs basically take the ‘brakes’ off the immune system, which helps it recognize and attack cancer cells.

Chimeric antigen receptor (CAR) T-cell therapy: This therapy takes some T-cells from a patient's blood, mixes them with a special virus that makes the T-cells learn how to attach to tumor cells, and then gives the cells back to the patient so they can find, attach to, and kill the cancer.

Cytokines: This treatment uses cytokines (small proteins that carry messages between cells) to stimulate the immune cells to attack cancer.
Immunomodulators: This group of drugs generally boosts parts of the immune system to treat certain types of cancer.

Cancer vaccines: Vaccines are substances put into the body to start an immune response against certain diseases. We usually think of them as being given to healthy people to help prevent infections. But some vaccines can help prevent or treat cancer.

Monoclonal antibodies (mAbs or MoAbs): These are man-made versions of immune system proteins. mAbs can be very useful in treating cancer because they can be designed to attack a very specific part of a cancer cell.

I printed out the reports for her and she will be taking a deeper dive when she gets back to Boston. I will keep you posted on what she comes back with. One thing I have believed from the outset with this company is that the science is sound.
It is a bio company and things take time. That's something I have here.
Hey MAGA we run down here on Tobacco Road. Calvert Hall is a great school. Excellent lacrosse program. I'll be up there for the national convention in January.
Have a great weekend everyone! Homecoming game tonight!!
Cheers,
Coach